Errik Anderson

WelbeHealth provides full-service care to help seniors age well at home and in their community, often at no cost. Services include medical, coordination, home care, dental, transport, physical therapy, prescriptions, social activities and meals. Founded by a seasoned group of physician entrepreneurs, our leadership team hails from leading payer and provider organizations such as GoHealth Urgent Care, BAYADA Home Health, AirStrip Technologies, Evolent Health, and On Lok. With funding from leading venture investors, were looking for team members who are inspired to help us deliver on our mission of unlocking the full potential of the most vulnerable seniors. Our colleagues are energized by working in diverse groups toward our shared purpose, are eager to drive groundbreaking innovations, and have the courage to care for our participants with empathy and love.

Avitide, a Repligen Company, discovers, develops, manufactures and supplies custom and catalog biopharmaceutical affinity purification solutions to the biopharmaceutical industry. Avitide’s proprietary AVIPure™ affinity ligand portfolio sets the standard for precise affinity separations and consistent robust performance for its high-valued chromatographic products. Avitide develops these technologies with an industry-leading 3-month, concept to resin delivery service timeline that enables industry biopharmaceutical manufacturers and contract developers to achieve faster bioprocess development timelines, improved process economics, predictable scalability, and enable next-generation integrated continuous downstream processing. Avitide’s commercial resin manufacturing and supply operates under an ISO 9001:2015 quality management system and has been successfully audited for its quality systems and continuity of supply plan for its affinity chromatography products. Avitide has successfully deployed affinity purification technologies towards an array of biological molecules including enzymes, bispecific antibodies, therapeutic scaffolds, growth factors, hormones, insulins, blood factors, Fcfusions, cell-based therapies, vaccines, and gene therapy viral vectors. For more information, visit www.avitide.com.

Effective March 13, 2019, Arsanis completed a merger with X4 Pharmaceuticals, Inc. For continued news and updates, we encourage you to follow X4 at www.x4pharma.com to stay in touch and learn more.

WelbeHealth provides full-service care to help seniors age well at home and in their community, often at no cost. Services include medical, coordination, home care, dental, transport, physical therapy, prescriptions, social activities and meals. Founded by a seasoned group of physician entrepreneurs, our leadership team hails from leading payer and provider organizations such as GoHealth Urgent Care, BAYADA Home Health, AirStrip Technologies, Evolent Health, and On Lok. With funding from leading venture investors, were looking for team members who are inspired to help us deliver on our mission of unlocking the full potential of the most vulnerable seniors. Our colleagues are energized by working in diverse groups toward our shared purpose, are eager to drive groundbreaking innovations, and have the courage to care for our participants with empathy and love.

New England Free Jacks are the Major League Rugby franchise proudly representing all six states in New England.

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. From licensing our platforms, to working with us as a trusted discovery service partner, we have collaborated with over 170+ partners and counting including 18 of Fortune 50 Biopharmaceutical companies to enable the discovery of their next breakthrough biologic medicines. With Alloy, you can: • Access our ever-growing stable of antibody and bispecific discovery platforms that blend in vivo and in vitro wet-lab capabilities with AI/ML. Discover with us through our services or by licensing our technologies for use in your lab. • Unlock intracellular targets with the therapeutic potential of T cell receptor (TCR) modalities through our fully integrated Keyway™ TCRm discovery service offering. • Reach genetic disease targets at the nucleic acid level with our novel AntiClastic™ ASO Format, which enhances the molecules potency while minimizing off-target interaction and inflammatory response. • Co-build new biotechnology companies that leverage our core platforms and service capabilities with Alloys affiliated Venture Studio, 82VS. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Boston, MA, with labs in Cambridge, U.K.; Basel, CH; and Athens, GA. We reinvest 100% of our revenue back into innovation and access to innovation. Reach out, follow, and visit our website, to learn more about how we can make better medicines, together. https://www.alloytx.com/

Founded in 2014, we’re America’s largest venture firm for individual investors and VC investing partner to over 11,000 individuals and institutions. Offerings include institutional-grade funds with large diversified portfolios and deal-by-deal investing through our Syndicates. Investment minimum is $10,000. • Top-20 VC Firm (Time Magazine ’25) • Top-Decile Investment Performance (Carta Benchmarks ‘25) • Top 20 VC Firm (CB Insights 24) • Top 50 Unicorn VC (Stanford GSB Research ‘25) • Top 3 Most Active US VC Firm (PitchBook ‘18 - ‘24) • Most Founder Friendly Investor List (Inc. Magazine ‘24) • Worlds Most Innovative Companies (Fast Company 22) • #1 Most Active Venture Firm in the US (PitchBook 22 & 23) • Top 20 Venture Firm (CB Insights 24) • Worlds Most Innovative Companies (Fast Company 22) • Portfolio of 1,600+ current and historical companies • 40+ full-time VC investors • Founders get access to our community of 850,000+ members and 6,000+ Experts. Offers of securities made only to eligible investors by formal offering documents describing risks, terms, and other important information that must be considered before investing. Example portfolio companies shown for illustrative purposes only, do not necessarily reflect investment outcomes that were or would be obtained by any AV fund or investor, and are not available to future investors, except potentially in follow-on investments. Venture capital investing involves substantial risk, including risk of loss of all capital invested. Past performance does not guarantee future results. The content on this account is intended solely for persons located in the U.S. and is not directed at, and must not be acted upon, by any person in the United Kingdom. UK residents seeking information about AV should refer only to communications issued by Alumni Ventures UK LLP, which provides information solely on a non-promotional basis and only distributes Financial Promotions to eligible recipients in accordance with UK law.